KR20090122994A - 테트라사이클린류를 함유하는 항염증성 조성물 및 이의 치료 용도 - Google Patents
테트라사이클린류를 함유하는 항염증성 조성물 및 이의 치료 용도 Download PDFInfo
- Publication number
- KR20090122994A KR20090122994A KR1020097021550A KR20097021550A KR20090122994A KR 20090122994 A KR20090122994 A KR 20090122994A KR 1020097021550 A KR1020097021550 A KR 1020097021550A KR 20097021550 A KR20097021550 A KR 20097021550A KR 20090122994 A KR20090122994 A KR 20090122994A
- Authority
- KR
- South Korea
- Prior art keywords
- tetracycline
- composition
- inflammatory
- tetracyclines
- tetracycline compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000004098 Tetracycline Substances 0.000 title claims abstract description 247
- 235000019364 tetracycline Nutrition 0.000 title claims abstract description 245
- 150000003522 tetracyclines Chemical class 0.000 title claims abstract description 171
- 239000000203 mixture Substances 0.000 title claims description 156
- 229940040944 tetracyclines Drugs 0.000 title claims description 64
- 230000003110 anti-inflammatory effect Effects 0.000 title claims description 33
- 229960002180 tetracycline Drugs 0.000 claims abstract description 183
- 229930101283 tetracycline Natural products 0.000 claims abstract description 181
- -1 tetracycline compound Chemical class 0.000 claims abstract description 113
- 229910052751 metal Inorganic materials 0.000 claims abstract description 74
- 239000002184 metal Substances 0.000 claims abstract description 74
- 208000027866 inflammatory disease Diseases 0.000 claims abstract description 44
- 238000010521 absorption reaction Methods 0.000 claims abstract description 32
- 238000000034 method Methods 0.000 claims abstract description 31
- 239000003112 inhibitor Substances 0.000 claims abstract description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
- 239000011575 calcium Substances 0.000 claims description 51
- 229910052791 calcium Inorganic materials 0.000 claims description 51
- 150000001875 compounds Chemical class 0.000 claims description 51
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 44
- 210000002784 stomach Anatomy 0.000 claims description 44
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 claims description 43
- 229960003722 doxycycline Drugs 0.000 claims description 42
- 150000003839 salts Chemical class 0.000 claims description 33
- 210000000936 intestine Anatomy 0.000 claims description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 24
- 235000013305 food Nutrition 0.000 claims description 23
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 16
- 206010000496 acne Diseases 0.000 claims description 16
- 201000004700 rosacea Diseases 0.000 claims description 16
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 15
- 208000035475 disorder Diseases 0.000 claims description 15
- 229910052749 magnesium Inorganic materials 0.000 claims description 15
- 239000011777 magnesium Substances 0.000 claims description 15
- 210000000813 small intestine Anatomy 0.000 claims description 13
- 230000002496 gastric effect Effects 0.000 claims description 12
- 150000002739 metals Chemical class 0.000 claims description 12
- 230000002093 peripheral effect Effects 0.000 claims description 12
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 235000012054 meals Nutrition 0.000 claims description 9
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 8
- 241000894006 Bacteria Species 0.000 claims description 8
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 8
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 8
- 229940041616 menthol Drugs 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 239000004100 Oxytetracycline Substances 0.000 claims description 7
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 7
- 229960000625 oxytetracycline Drugs 0.000 claims description 7
- 235000019366 oxytetracycline Nutrition 0.000 claims description 7
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 claims description 7
- 239000003242 anti bacterial agent Substances 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 239000011701 zinc Substances 0.000 claims description 5
- 229910052725 zinc Inorganic materials 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 229940088710 antibiotic agent Drugs 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 239000004615 ingredient Substances 0.000 claims description 4
- 229910052742 iron Inorganic materials 0.000 claims description 4
- 231100000252 nontoxic Toxicity 0.000 claims description 4
- 230000003000 nontoxic effect Effects 0.000 claims description 4
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- 208000002177 Cataract Diseases 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 201000009906 Meningitis Diseases 0.000 claims description 3
- 208000008589 Obesity Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 206010063837 Reperfusion injury Diseases 0.000 claims description 3
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- 239000011230 binding agent Substances 0.000 claims description 3
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 claims description 3
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 claims description 3
- 206010015037 epilepsy Diseases 0.000 claims description 3
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 235000020824 obesity Nutrition 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 201000003068 rheumatic fever Diseases 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 3
- 239000011573 trace mineral Substances 0.000 claims description 3
- 235000013619 trace mineral Nutrition 0.000 claims description 3
- 208000030767 Autoimmune encephalitis Diseases 0.000 claims description 2
- 239000004099 Chlortetracycline Substances 0.000 claims description 2
- 206010010904 Convulsion Diseases 0.000 claims description 2
- 206010020751 Hypersensitivity Diseases 0.000 claims description 2
- 206010028372 Muscular weakness Diseases 0.000 claims description 2
- 206010046851 Uveitis Diseases 0.000 claims description 2
- 230000007815 allergy Effects 0.000 claims description 2
- 229960004475 chlortetracycline Drugs 0.000 claims description 2
- 235000019365 chlortetracycline Nutrition 0.000 claims description 2
- 206010009887 colitis Diseases 0.000 claims description 2
- 235000015872 dietary supplement Nutrition 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 230000036473 myasthenia Effects 0.000 claims description 2
- 230000003637 steroidlike Effects 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 206010043778 thyroiditis Diseases 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 230000001419 dependent effect Effects 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 claims 1
- 239000006072 paste Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 229960005069 calcium Drugs 0.000 description 49
- 238000011282 treatment Methods 0.000 description 49
- 230000004054 inflammatory process Effects 0.000 description 42
- 206010061218 Inflammation Diseases 0.000 description 39
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 30
- 230000000694 effects Effects 0.000 description 29
- 150000001768 cations Chemical class 0.000 description 27
- 230000000968 intestinal effect Effects 0.000 description 27
- 239000006187 pill Substances 0.000 description 20
- 230000002757 inflammatory effect Effects 0.000 description 19
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 18
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 18
- 229960004023 minocycline Drugs 0.000 description 17
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 16
- 239000000306 component Substances 0.000 description 16
- 229940091250 magnesium supplement Drugs 0.000 description 15
- 229910000019 calcium carbonate Inorganic materials 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- 239000003814 drug Substances 0.000 description 14
- 206010003246 arthritis Diseases 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 230000037396 body weight Effects 0.000 description 13
- XMEVHPAGJVLHIG-FMZCEJRJSA-N chembl454950 Chemical group [Cl-].C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H]([NH+](C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O XMEVHPAGJVLHIG-FMZCEJRJSA-N 0.000 description 13
- 210000000987 immune system Anatomy 0.000 description 13
- 230000005764 inhibitory process Effects 0.000 description 13
- 229960004989 tetracycline hydrochloride Drugs 0.000 description 13
- 239000004480 active ingredient Substances 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 12
- 230000003115 biocidal effect Effects 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 210000001035 gastrointestinal tract Anatomy 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 9
- 102000004127 Cytokines Human genes 0.000 description 9
- 108090000695 Cytokines Proteins 0.000 description 9
- 239000001110 calcium chloride Substances 0.000 description 9
- 229960002713 calcium chloride Drugs 0.000 description 9
- 229910001628 calcium chloride Inorganic materials 0.000 description 9
- 230000003111 delayed effect Effects 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 239000002702 enteric coating Substances 0.000 description 9
- 238000009505 enteric coating Methods 0.000 description 9
- 235000019359 magnesium stearate Nutrition 0.000 description 9
- 229920002785 Croscarmellose sodium Polymers 0.000 description 8
- 235000021355 Stearic acid Nutrition 0.000 description 8
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 8
- 230000000845 anti-microbial effect Effects 0.000 description 8
- 229960005168 croscarmellose Drugs 0.000 description 8
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 8
- 150000004683 dihydrates Chemical class 0.000 description 8
- 229910001629 magnesium chloride Inorganic materials 0.000 description 8
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 8
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 239000008117 stearic acid Substances 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 241001303601 Rosacea Species 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 235000005911 diet Nutrition 0.000 description 7
- 230000037213 diet Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 210000000265 leukocyte Anatomy 0.000 description 7
- 230000000770 proinflammatory effect Effects 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 230000032258 transport Effects 0.000 description 7
- IMLJLCJZQLGHJS-JEKSYDDFSA-N (4s,4ar,5s,5ar,6s,12ar)-4-(dimethylamino)-1,5,6,10,11,12a-hexahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide;dihydrate Chemical compound O.O.C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O IMLJLCJZQLGHJS-JEKSYDDFSA-N 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 230000002378 acidificating effect Effects 0.000 description 6
- 235000012041 food component Nutrition 0.000 description 6
- 159000000003 magnesium salts Chemical class 0.000 description 6
- 201000008482 osteoarthritis Diseases 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 208000035143 Bacterial infection Diseases 0.000 description 5
- 206010070840 Gastrointestinal tract irritation Diseases 0.000 description 5
- 206010042674 Swelling Diseases 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 208000022362 bacterial infectious disease Diseases 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- HALQELOKLVRWRI-VDBOFHIQSA-N doxycycline hyclate Chemical compound O.[Cl-].[Cl-].CCO.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H]([NH+](C)C)[C@@H]1[C@H]2O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H]([NH+](C)C)[C@@H]1[C@H]2O HALQELOKLVRWRI-VDBOFHIQSA-N 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000000395 magnesium oxide Substances 0.000 description 5
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 5
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 5
- 230000001575 pathological effect Effects 0.000 description 5
- 238000012552 review Methods 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 238000012384 transportation and delivery Methods 0.000 description 5
- 241000282412 Homo Species 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 206010047700 Vomiting Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000005428 food component Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 239000008203 oral pharmaceutical composition Substances 0.000 description 4
- 208000017520 skin disease Diseases 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 229940063678 vibramycin Drugs 0.000 description 4
- 230000008673 vomiting Effects 0.000 description 4
- FZKWRPSUNUOXKJ-CVHRZJFOSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydrate Chemical compound O.C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O FZKWRPSUNUOXKJ-CVHRZJFOSA-N 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 229920003135 Eudragit® L 100-55 Polymers 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 102000005741 Metalloproteases Human genes 0.000 description 3
- 108010006035 Metalloproteases Proteins 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 206010033733 Papule Diseases 0.000 description 3
- 206010037888 Rash pustular Diseases 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 229940124599 anti-inflammatory drug Drugs 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 description 3
- 235000011010 calcium phosphates Nutrition 0.000 description 3
- 159000000007 calcium salts Chemical class 0.000 description 3
- 208000015114 central nervous system disease Diseases 0.000 description 3
- 239000002738 chelating agent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 description 3
- OKISBDHRUPZLOC-UHFFFAOYSA-N gallin Chemical compound OC(=O)C1=CC=CC=C1C1C2=CC=C(O)C(O)=C2OC2=C(O)C(O)=CC=C21 OKISBDHRUPZLOC-UHFFFAOYSA-N 0.000 description 3
- 210000004907 gland Anatomy 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 229940099993 magnesium oxide 75 mg Drugs 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 229940065037 oracea Drugs 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 208000029561 pustule Diseases 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 108010074051 C-Reactive Protein Proteins 0.000 description 2
- 102100032752 C-reactive protein Human genes 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 2
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 2
- 241000186427 Cutibacterium acnes Species 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 241000227653 Lycopersicon Species 0.000 description 2
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 229940069428 antacid Drugs 0.000 description 2
- 239000003159 antacid agent Substances 0.000 description 2
- 230000001458 anti-acid effect Effects 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 229940016060 calcium carbonate 150 mg Drugs 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- ZOMBKNNSYQHRCA-UHFFFAOYSA-J calcium sulfate hemihydrate Chemical compound O.[Ca+2].[Ca+2].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O ZOMBKNNSYQHRCA-UHFFFAOYSA-J 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 150000001805 chlorine compounds Chemical class 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000005417 food ingredient Substances 0.000 description 2
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000031891 intestinal absorption Effects 0.000 description 2
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 229960003284 iron Drugs 0.000 description 2
- 210000001503 joint Anatomy 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 238000011866 long-term treatment Methods 0.000 description 2
- 210000003563 lymphoid tissue Anatomy 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000002831 pharmacologic agent Substances 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 201000000306 sarcoidosis Diseases 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 230000009919 sequestration Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000012385 systemic delivery Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000020192 tolerance induction in gut-associated lymphoid tissue Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- YZEUHQHUFTYLPH-UHFFFAOYSA-N 2-nitroimidazole Chemical compound [O-][N+](=O)C1=NC=CN1 YZEUHQHUFTYLPH-UHFFFAOYSA-N 0.000 description 1
- WTJXVDPDEQKTCV-UHFFFAOYSA-N 4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydron;chloride Chemical compound Cl.C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2C1CC1C(N(C)C)C(=O)C(C(N)=O)=C(O)C1(O)C2=O WTJXVDPDEQKTCV-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000020154 Acnes Diseases 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 1
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 239000004604 Blowing Agent Substances 0.000 description 1
- JJDDPDHSLLONIF-UHFFFAOYSA-N C=C.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O Chemical compound C=C.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O JJDDPDHSLLONIF-UHFFFAOYSA-N 0.000 description 1
- 102000013830 Calcium-Sensing Receptors Human genes 0.000 description 1
- 108010050543 Calcium-Sensing Receptors Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical class [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 241001427367 Gardena Species 0.000 description 1
- 108010008488 Glycylglycine Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102100037611 Lysophospholipase Human genes 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical group [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 206010072139 Ocular rosacea Diseases 0.000 description 1
- 108010058864 Phospholipases A2 Proteins 0.000 description 1
- 241000589774 Pseudomonas sp. Species 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- RJZNFXWQRHAVBP-UHFFFAOYSA-I aluminum;magnesium;pentahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Al+3] RJZNFXWQRHAVBP-UHFFFAOYSA-I 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000011861 anti-inflammatory therapy Methods 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000011203 antimicrobial therapy Methods 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 235000015197 apple juice Nutrition 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 150000001669 calcium Chemical class 0.000 description 1
- LLSDKQJKOVVTOJ-UHFFFAOYSA-L calcium chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Ca+2] LLSDKQJKOVVTOJ-UHFFFAOYSA-L 0.000 description 1
- 229940052299 calcium chloride dihydrate Drugs 0.000 description 1
- 229940069978 calcium supplement Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000005323 carbonate salts Chemical class 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 201000011529 cardiovascular cancer Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- GJPGCACMCURAKH-YQCFNCLSSA-L chembl2364574 Chemical compound [Ca+2].O=C1C2=C([O-])C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O.O=C1C2=C([O-])C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O GJPGCACMCURAKH-YQCFNCLSSA-L 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 208000034391 chronic adult periodontitis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000001277 chronic periodontitis Diseases 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical compound OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229960003788 doxycycline calcium Drugs 0.000 description 1
- 201000004997 drug-induced lupus erythematosus Diseases 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 230000009246 food effect Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229940043257 glycylglycine Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000010440 gypsum Substances 0.000 description 1
- 229910052602 gypsum Inorganic materials 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 159000000014 iron salts Chemical class 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 229940064321 magnesium oxide 100 mg Drugs 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 150000002736 metal compounds Chemical class 0.000 description 1
- 125000005641 methacryl group Chemical group 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- GLMUAFMGXXHGLU-VQAITOIOSA-N minocycline hydrochloride Chemical compound [H+].[Cl-].C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O GLMUAFMGXXHGLU-VQAITOIOSA-N 0.000 description 1
- 229960002421 minocycline hydrochloride Drugs 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000017095 negative regulation of cell growth Effects 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 229960003753 nitric oxide Drugs 0.000 description 1
- 230000001937 non-anti-biotic effect Effects 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- 230000024715 positive regulation of secretion Effects 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 229940005657 pyrophosphoric acid Drugs 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000008458 response to injury Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 229960004089 tigecycline Drugs 0.000 description 1
- FPZLLRFZJZRHSY-HJYUBDRYSA-N tigecycline Chemical class C([C@H]1C2)C3=C(N(C)C)C=C(NC(=O)CNC(C)(C)C)C(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O FPZLLRFZJZRHSY-HJYUBDRYSA-N 0.000 description 1
- 235000015113 tomato pastes and purées Nutrition 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Inorganic Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89656407P | 2007-03-23 | 2007-03-23 | |
| US60/896,564 | 2007-03-23 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020137028763A Division KR20130137696A (ko) | 2007-03-23 | 2008-03-20 | 테트라사이클린류를 함유하는 항염증성 조성물 및 이의 치료 용도 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20090122994A true KR20090122994A (ko) | 2009-12-01 |
Family
ID=39651298
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020097021550A Ceased KR20090122994A (ko) | 2007-03-23 | 2008-03-20 | 테트라사이클린류를 함유하는 항염증성 조성물 및 이의 치료 용도 |
| KR1020137028763A Abandoned KR20130137696A (ko) | 2007-03-23 | 2008-03-20 | 테트라사이클린류를 함유하는 항염증성 조성물 및 이의 치료 용도 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020137028763A Abandoned KR20130137696A (ko) | 2007-03-23 | 2008-03-20 | 테트라사이클린류를 함유하는 항염증성 조성물 및 이의 치료 용도 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20080233206A1 (https=) |
| EP (1) | EP2125018A1 (https=) |
| JP (1) | JP5395052B2 (https=) |
| KR (2) | KR20090122994A (https=) |
| CN (2) | CN102688492A (https=) |
| AP (1) | AP2657A (https=) |
| AU (1) | AU2008231033B2 (https=) |
| EA (1) | EA016206B1 (https=) |
| WO (1) | WO2008118744A1 (https=) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20150104102A (ko) * | 2012-11-27 | 2015-09-14 | 호비온 사이언티아 리미티드 | 테트라사이클린 국소 제제, 제조방법, 및 이의 용도 |
| KR20230092754A (ko) * | 2021-12-17 | 2023-06-26 | 주식회사 케이씨앤씨 | 클로르테트라사이클린을 포함하는 고양이 전염성 복막염 치료용 조성물 |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103040773A (zh) | 2003-07-25 | 2013-04-17 | 沃纳奇尔科特有限责任公司 | 多西环素金属络合物固体剂型 |
| AU2006206359B2 (en) * | 2005-01-21 | 2011-03-31 | Allergan Pharmaceuticals International Limited | A tetracycline metal complex in a solid dosage form |
| KR101799304B1 (ko) * | 2010-05-12 | 2017-11-20 | 렘펙스 파머수티클스 인코퍼레이티드 | 테트라사이클린 조성물 |
| US9119793B1 (en) | 2011-06-28 | 2015-09-01 | Medicis Pharmaceutical Corporation | Gastroretentive dosage forms for doxycycline |
| CN103536607A (zh) * | 2012-07-10 | 2014-01-29 | 邵金辉 | 土霉素，普罗帕酮和安乃近的抗肿瘤作用 |
| US10842802B2 (en) | 2013-03-15 | 2020-11-24 | Medicis Pharmaceutical Corporation | Controlled release pharmaceutical dosage forms |
| ITMI20132066A1 (it) * | 2013-12-11 | 2015-06-12 | Farmatron Ltd | Sistemi terapeutici a rilascio modificato per la somministrazione orale di mentolo nel trattamento delle malattie intestinali |
| WO2015153864A2 (en) * | 2014-04-02 | 2015-10-08 | Hopkins Patricia T | Methods for treating inflammatory conditions |
| CN103933539B (zh) * | 2014-04-16 | 2017-01-11 | 西北农林科技大学 | 一种含有四环素的药物组合物及其应用 |
| KR20170134514A (ko) | 2015-03-23 | 2017-12-06 | 바이오팜엑스 인코포레이티드 | 피부과 사용을 위한 약학 테트라사이클린 조성물 |
| CN105998037A (zh) * | 2016-06-16 | 2016-10-12 | 汕头大学 | 多西环素在制备治疗或预防衰老性疾病的药物中的用途 |
| CO2017001953A1 (es) * | 2017-02-27 | 2018-08-31 | Corporacion Univ Lasallista | Método de encapsulación de tetraciclinas |
| BR112021007969A2 (pt) * | 2018-10-29 | 2021-07-27 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | complexos de tetraciclina com atividade controlada |
| CN110169973A (zh) * | 2019-06-11 | 2019-08-27 | 贾树森 | 一种用于颈椎康复的外用药物组合物 |
| CN111870607A (zh) * | 2020-07-09 | 2020-11-03 | 温州医科大学 | 盐酸米诺环素作为制备治疗自身免疫性葡萄膜炎药物的应用及其治疗方法 |
| CN116655491B (zh) * | 2023-05-12 | 2025-01-28 | 常州大学 | 一种多功能抗菌纳米材料TCFNPs及其制备方法和应用 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2736725A (en) * | 1954-03-11 | 1956-02-28 | American Cyanamid Co | Complexes of tetracycline antibiotics and preparation of same |
| US2766124A (en) * | 1954-05-25 | 1956-10-09 | American Cyanamid Co | Antibiotic-containing ice composition |
| US2806789A (en) * | 1954-09-10 | 1957-09-17 | American Cyanamid Co | Enhancement of therapeutic efficacy of antibiotics |
| GB901209A (en) * | 1957-10-23 | 1962-07-18 | Pfizer & Co C | 6-deoxytetracyclines and compositions containing same |
| GB901107A (en) * | 1959-06-29 | 1962-07-11 | Pfizer | Therapeutic composition and method of preparing same |
| GB894619A (en) * | 1959-09-11 | 1962-04-26 | Pfizer & Co C | Stabilized liquid preparations comprising tetracycline antibiotics |
| FR1430859A (https=) * | 1960-05-23 | 1966-05-25 | ||
| US3275513A (en) * | 1963-05-29 | 1966-09-27 | American Cyanamid Co | Stable calcium tetracycline compositions |
| US4061676A (en) * | 1970-07-03 | 1977-12-06 | Ivan Villax | Recovery of doxycycline and products thereof |
| US3957980A (en) * | 1972-10-26 | 1976-05-18 | Pfizer Inc. | Doxycycline parenteral compositions |
| US4060605A (en) * | 1973-09-28 | 1977-11-29 | Ankerfarm, S.P.A. | Water-soluble derivative of 6-deoxy-tetracyclines |
| DK153784C (da) * | 1973-09-28 | 1989-01-23 | Pfizer | Analogifremgangsmaade til fremstilling af 2-n-(methioninomethyl)doxycyclin eller salte deraf |
| US4150111A (en) * | 1974-05-28 | 1979-04-17 | Allister Warren | Enteric coated magnesium chloride |
| JPS51107134A (en) * | 1975-03-17 | 1976-09-22 | Asahi Optical Co Ltd | Shotenmenkenshutsusochi |
| US4081527A (en) * | 1976-12-07 | 1978-03-28 | Pfizer Inc. | Chlortetracycline compositions |
| US4126680A (en) * | 1977-04-27 | 1978-11-21 | Pfizer Inc. | Tetracycline antibiotic compositions |
| US4837030A (en) * | 1987-10-06 | 1989-06-06 | American Cyanamid Company | Novel controlled release formulations of tetracycline compounds |
| EP0327295A3 (en) * | 1988-02-01 | 1989-09-06 | F.H. FAULDING & CO. LTD. | Tetracycline dosage form |
| US5250442A (en) * | 1993-04-08 | 1993-10-05 | Orestes Cabezas | Method of treating rheumatoid arthritis using tetracycline |
| US5538954A (en) * | 1994-06-24 | 1996-07-23 | A/S Dumex (Dumex Ltd.) | Salts of tetracyclines |
| US5614206A (en) * | 1995-03-07 | 1997-03-25 | Wright Medical Technology, Inc. | Controlled dissolution pellet containing calcium sulfate |
| DE69627855T2 (de) * | 1995-06-13 | 2004-03-11 | Nippon Meat Packers, Inc. | Orales mittel gegen rheumatische arthritis und funktionelles nahrungsmittel |
| US5789395A (en) * | 1996-08-30 | 1998-08-04 | The Research Foundation Of State University Of New York | Method of using tetracycline compounds for inhibition of endogenous nitric oxide production |
| US5968896A (en) * | 1998-01-16 | 1999-10-19 | Beth Israel Deaconess Medical Center | Nutritional supplement for preoperative feeding |
| CA2360938C (en) * | 1999-02-02 | 2008-01-08 | Warren Oliver Haggard | Controlled release composite |
| US6765000B2 (en) * | 1999-03-17 | 2004-07-20 | Bonner Jr Ernest L | Treatment for reactive arthritis or bursitis |
| US7884090B2 (en) * | 1999-03-17 | 2011-02-08 | Ernest L. Bonner, Jr. | Compositions and methods for the treatment of arthritis |
| US6946118B1 (en) * | 1999-09-14 | 2005-09-20 | Orapharma, Inc. | Formulations for treating or preventing mucositis |
| US6638532B2 (en) * | 2000-02-24 | 2003-10-28 | Advancis Pharmaceutical Corp. | Tetracycline—doxycycline antibiotic composition |
| US6887492B2 (en) * | 2000-12-14 | 2005-05-03 | Leiner Health Services Corp. | Magnesium plus interactive agent delivery |
| AU2002303250B2 (en) * | 2001-04-05 | 2006-05-25 | Collagenex Pharmaceuticals, Inc. | Methods of treating acne |
| US7211267B2 (en) * | 2001-04-05 | 2007-05-01 | Collagenex Pharmaceuticals, Inc. | Methods of treating acne |
| MXPA03009995A (es) * | 2001-05-09 | 2004-06-30 | Univ Michigan | Uso de composiciones para tratar rosacea. |
| US20060194773A1 (en) * | 2001-07-13 | 2006-08-31 | Paratek Pharmaceuticals, Inc. | Tetracyline compounds having target therapeutic activities |
| US7122578B2 (en) * | 2001-09-11 | 2006-10-17 | Alain Martin | Method and composition for treating mammalian diseases and injuries which cause pain, erythema, swelling, crusting, ischemia scarring and excess white blood cell infiltration |
| NO315915B1 (no) * | 2002-02-25 | 2003-11-10 | Sintef Elektronikk Og Kybernet | Fj¶rvekt |
| AU2003245295B2 (en) * | 2002-05-20 | 2008-01-03 | Collagenex Pharmaceuticals, Inc. | Methods of treating allergic reactions |
| CN103040773A (zh) * | 2003-07-25 | 2013-04-17 | 沃纳奇尔科特有限责任公司 | 多西环素金属络合物固体剂型 |
| EP2269985A3 (en) * | 2004-10-25 | 2011-09-21 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds |
| AU2006206359B2 (en) * | 2005-01-21 | 2011-03-31 | Allergan Pharmaceuticals International Limited | A tetracycline metal complex in a solid dosage form |
| US7919483B2 (en) * | 2005-06-24 | 2011-04-05 | Medicis Pharmaceutical Corporation | Method for the treatment of acne |
-
2008
- 2008-03-20 AU AU2008231033A patent/AU2008231033B2/en not_active Ceased
- 2008-03-20 JP JP2010501103A patent/JP5395052B2/ja not_active Expired - Fee Related
- 2008-03-20 KR KR1020097021550A patent/KR20090122994A/ko not_active Ceased
- 2008-03-20 KR KR1020137028763A patent/KR20130137696A/ko not_active Abandoned
- 2008-03-20 CN CN2012101925621A patent/CN102688492A/zh active Pending
- 2008-03-20 EA EA200901289A patent/EA016206B1/ru not_active IP Right Cessation
- 2008-03-20 WO PCT/US2008/057646 patent/WO2008118744A1/en not_active Ceased
- 2008-03-20 EP EP08732557A patent/EP2125018A1/en not_active Ceased
- 2008-03-20 AP AP2009004979A patent/AP2657A/xx active
- 2008-03-20 CN CN200880016401A patent/CN101678108A/zh active Pending
- 2008-03-21 US US12/053,020 patent/US20080233206A1/en not_active Abandoned
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20150104102A (ko) * | 2012-11-27 | 2015-09-14 | 호비온 사이언티아 리미티드 | 테트라사이클린 국소 제제, 제조방법, 및 이의 용도 |
| KR20230092754A (ko) * | 2021-12-17 | 2023-06-26 | 주식회사 케이씨앤씨 | 클로르테트라사이클린을 포함하는 고양이 전염성 복막염 치료용 조성물 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2010522240A (ja) | 2010-07-01 |
| AP2657A (en) | 2013-05-07 |
| US20080233206A1 (en) | 2008-09-25 |
| EA016206B1 (ru) | 2012-03-30 |
| JP5395052B2 (ja) | 2014-01-22 |
| AU2008231033B2 (en) | 2012-08-30 |
| AP2009004979A0 (en) | 2009-10-31 |
| AU2008231033A1 (en) | 2008-10-02 |
| CN102688492A (zh) | 2012-09-26 |
| WO2008118744A1 (en) | 2008-10-02 |
| EP2125018A1 (en) | 2009-12-02 |
| CN101678108A (zh) | 2010-03-24 |
| EA200901289A1 (ru) | 2010-02-26 |
| KR20130137696A (ko) | 2013-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5395052B2 (ja) | 炎症を処置するための組成物および方法 | |
| TW389696B (en) | Accelerated release composition containing bromocriptine | |
| JP3806427B2 (ja) | 新規鎮痛剤 | |
| HRP930755A2 (en) | Synergistic combination of a substance with gastric acid secretion inhibiting effect and an acid degradable antibiotic | |
| JP5769308B2 (ja) | 貧血又はｈ．ピロリ感染に用いる単（鉄ヒドロキシピロン）及び組み合わせ（鉄ヒドロキシピロン及び胃腸炎抑止剤）組成物 | |
| JP2011140521A (ja) | タキサンにより惹起される神経毒性を予防又は軽減するための薬剤 | |
| HU210330B (en) | Process for production of preparations containing n-(4-chlorophenyl)-n"-cyano-n'-(6-cyano-3,4-dyhidro-3-hydroxy-2,2-dimethyl-2h-1 benzopyran-4-yl)-guanidine prophylaxis and/or treatment of gastrointestinal ulcer | |
| Majewski | A current opinion on the safety and efficacy of doxycycline including parenteral administration–A review | |
| RU2541092C2 (ru) | Бисглицинат-хелат железа для использования в пероральном лечении анемии у пациентов с целиакией | |
| CA2476939A1 (en) | Pharmaceutical combinations of cox-2 inhibitors and opiates | |
| Junita et al. | The effect of glutathione as adjuvant therapy on levels of TNF-α and IL-10 in wistar rat peritonitis model | |
| JP2015193660A (ja) | 経口ｂ１２治療 | |
| EP1021087A1 (en) | Serotonin containing formulation for oral administration and method of use | |
| JP2010106019A (ja) | リマプロストを含有してなる癌化学療法に起因する末梢神経障害予防、治療および／または症状軽減剤 | |
| Chomczynski et al. | Compositions and methods for anti-inflammatory treatments | |
| Ashida et al. | Clinical study on the pathophysiology and treatment of PPI-resistant ulcers | |
| Gofur et al. | Drug choice to lowering risk contiguity with Morbus Hansen disease: A review article | |
| AU2012230089B2 (en) | Anti-inflammatory compositions comprising tetracyclines and use thereof in therapy | |
| HRP20030382A2 (en) | A combination comprising camptothecin and a stilbene derivative for the treatment of cancer | |
| JP4614638B2 (ja) | 鎮痛剤組成物 | |
| CA2849732A1 (en) | Buffered upper gi absorption promoter | |
| EP1747010A1 (en) | Use of sulglicotide for the treatment of mucositis | |
| JP2586542B2 (ja) | 牛の第四胃変位の治療剤 | |
| AU2012276476A1 (en) | Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation | |
| JP2007091761A (ja) | Ｈ．ｐｙｌｏｒｉに起因する胃腸障害の処置のためのスピラマイシン含有薬剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20091015 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| AMND | Amendment | ||
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| AMND | Amendment | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20110701 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20121116 Patent event code: PE09021S01D |
|
| AMND | Amendment | ||
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20130627 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20121116 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |
|
| AMND | Amendment | ||
| J201 | Request for trial against refusal decision | ||
| PJ0201 | Trial against decision of rejection |
Patent event date: 20130930 Comment text: Request for Trial against Decision on Refusal Patent event code: PJ02012R01D Patent event date: 20130627 Comment text: Decision to Refuse Application Patent event code: PJ02011S01I Appeal kind category: Appeal against decision to decline refusal Decision date: 20140304 Appeal identifier: 2013101007190 Request date: 20130930 |
|
| A107 | Divisional application of patent | ||
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20131030 |
|
| PB0901 | Examination by re-examination before a trial |
Comment text: Amendment to Specification, etc. Patent event date: 20130930 Patent event code: PB09011R02I Comment text: Request for Trial against Decision on Refusal Patent event date: 20130930 Patent event code: PB09011R01I Comment text: Amendment to Specification, etc. Patent event date: 20130218 Patent event code: PB09011R02I Comment text: Amendment to Specification, etc. Patent event date: 20110701 Patent event code: PB09011R02I Comment text: Amendment to Specification, etc. Patent event date: 20091026 Patent event code: PB09011R02I |
|
| B601 | Maintenance of original decision after re-examination before a trial | ||
| PB0601 | Maintenance of original decision after re-examination before a trial |
Comment text: Report of Result of Re-examination before a Trial Patent event code: PB06011S01D Patent event date: 20131125 |
|
| E801 | Decision on dismissal of amendment | ||
| PE0801 | Dismissal of amendment |
Patent event code: PE08012E01D Comment text: Decision on Dismissal of Amendment Patent event date: 20131126 Patent event code: PE08011R01I Comment text: Amendment to Specification, etc. Patent event date: 20130930 Patent event code: PE08011R01I Comment text: Amendment to Specification, etc. Patent event date: 20130218 Patent event code: PE08011R01I Comment text: Amendment to Specification, etc. Patent event date: 20110701 Patent event code: PE08011R01I Comment text: Amendment to Specification, etc. Patent event date: 20091026 |
|
| PC1202 | Submission of document of withdrawal before decision of registration |
Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment) Patent event code: PC12021R01D Patent event date: 20140214 |
|
| WITB | Written withdrawal of application | ||
| J301 | Trial decision |
Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20130930 Effective date: 20140304 |
|
| PJ1301 | Trial decision |
Patent event code: PJ13011S01D Patent event date: 20140304 Comment text: Trial Decision on Objection to Decision on Refusal Appeal kind category: Appeal against decision to decline refusal Request date: 20130930 Decision date: 20140304 Appeal identifier: 2013101007190 |